Clinical Trials
664 trialsNCT05748171 2026-06-05
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Phase 2 Recruiting
NCT05963074 2026-06-05
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05207670 2026-06-03
MorningSun
Genentech, Inc.
Phase 2 Active not recruiting
NCT06745583 2026-06-03
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2 Recruiting
NCT03876769 2026-06-02
CASSIOPEIA
Novartis
Phase 2 Active not recruiting
NCT05020652 2026-06-02
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT05283720 2026-06-02
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT05660967 2026-06-02
EPCORE DLBCL-3
Genmab
Phase 2 Active not recruiting
NCT05952024 2026-06-02
ACRUE
AstraZeneca
Phase 2 Recruiting
NCT06500273 2026-06-02
ALPHA3
Allogene Therapeutics
Phase 2 Recruiting
NCT06539182 2026-06-02
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Dizal Pharmaceuticals
Phase 2 Recruiting
NCT05951959 2026-06-01
TrAVeRse
AstraZeneca
Phase 2 Active not recruiting
NCT05458297 2026-05-29
MK-2140-006
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06637501 2026-05-29
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2 Active not recruiting
NCT06890884 2026-05-29
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07387471 2026-05-29
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
Phase 2 Recruiting
NCT05144841 2026-05-28
MK-2140-004
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07221500 2026-05-28
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
Phase 2 Recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT07609823 2026-05-27
A Phase 2 Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2 Not yet recruiting
NCT04728893 2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06806033 2026-05-26
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT04570423 2026-05-22
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
Phase 2 Recruiting
NCT07271667 2026-05-22
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.
Phase 2 Recruiting
NCT06588478 2026-05-19
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 2 Recruiting
NCT02213926 2026-05-18
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma BV
Phase 2 Active not recruiting
NCT02943642 2026-05-18
Resimmune®
Virogen Biotechnology Inc.
Phase 2 Withdrawn
NCT06514794 2026-05-12
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
Phase 2 Recruiting
NCT07029737 2026-05-07
SOUND-MCL
AstraZeneca
Phase 2 Recruiting
NCT02227251 2026-05-06
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 2 Active not recruiting
NCT07569965 2026-05-06
FRONTIER
Miltenyi Biomedicine GmbH
Phase 2 Not yet recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT06508931 2026-05-05
DALY PED
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT07125872 2026-05-04
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT05156125 2026-04-30
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Oppilan Pharma Ltd
Phase 2 Terminated
NCT03902184 2026-04-29
TELLOMAK
Innate Pharma
Phase 2 Completed
NCT04844866 2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT06854653 2026-04-29
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
NCT04554914 2026-04-27
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT07082686 2026-04-27
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2 Recruiting
NCT03580655 2026-04-24
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT04414163 2026-04-24
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
ImmuneOncia Therapeutics Inc.
Phase 2 Active not recruiting
NCT07545603 2026-04-22
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Evopoint Biosciences Inc.
Phase 2 Recruiting
NCT07162181 2026-04-17
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Eli Lilly and Company
Phase 2 Active not recruiting
NCT07529405 2026-04-14
CurbMF
Virogen Biotechnology Inc.
Phase 2 Not yet recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05020015 2026-03-31
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Takeda
Phase 2 Active not recruiting
NCT03156790 2026-03-30
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia
medac GmbH
Phase 2 Terminated
NCT05147467 2026-03-27
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
NCT06915246 2026-03-27
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS LLC
Phase 2 Recruiting